These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7896411)

  • 21. Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients.
    Kager PA; Rees PH; Manguyu FM; Bhatt KM; Wellde BT; Hockmeyer WT; Lyerly WH
    Trop Geogr Med; 1984 Mar; 36(1):21-35. PubMed ID: 6328709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in the management of visceral leishmaniasis.
    Sundar S; Kumar A
    Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
    [No Abstract]   [Full Text] [Related]  

  • 23. Allopurinol in the treatment of visceral leishmaniasis.
    Kager PA; Rees PH; Wellde BT; Hockmeyer WT; Lyerly WH
    Trans R Soc Trop Med Hyg; 1981; 75(4):556-9. PubMed ID: 6275579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of kala-azar: old and new options.
    Zijlstra EE
    Trop Geogr Med; 1992 Jul; 44(3):288. PubMed ID: 1455546
    [No Abstract]   [Full Text] [Related]  

  • 25. Utility of lymph node aspiration in the diagnosis of visceral leishmaniasis in Sudan.
    Babiker ZO; Davidson R; Mazinda C; Kipngetich S; Ritmeijer K
    Am J Trop Med Hyg; 2007 Apr; 76(4):689-93. PubMed ID: 17426171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.
    Singh S; Gilman-Sachs A; Chang KP; Reed SG
    J Parasitol; 1995 Dec; 81(6):1000-3. PubMed ID: 8544037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Indian kala-azar with pentavalent antimony.
    Arya SC
    Lancet; 1995 Mar; 345(8949):584. PubMed ID: 7776791
    [No Abstract]   [Full Text] [Related]  

  • 28. Kala-azar in Madras city.
    Santhanakrishnan BR; Ramachandran A; Raju B
    Indian Pediatr; 1977 Jun; 14(6):471-3. PubMed ID: 203529
    [No Abstract]   [Full Text] [Related]  

  • 29. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar.
    Wali JP; Aggarwal P; Gupta U; Saluja S; Singh S
    J Infect Dis; 1992 Jul; 166(1):215-6. PubMed ID: 1607703
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of Indian Kala-azar with pentavalent antimony.
    Domingo P; Ferrer S; Kolle L; Muñoz C; Sambeat MA
    Lancet; 1995 Mar; 345(8949):584-5. PubMed ID: 7776793
    [No Abstract]   [Full Text] [Related]  

  • 31. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma.
    Sundar S; Rosenkaimer F; Murray HW
    J Infect Dis; 1994 Sep; 170(3):659-62. PubMed ID: 8077725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kala-azar--new developments in diagnosis and treatment.
    Aggarwal P; Handa R; Singh S; Wali JP
    Indian J Pediatr; 1999; 66(1):63-71. PubMed ID: 10798038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.
    Thakur CP; Kumar M; Pandey AK
    Am J Trop Med Hyg; 1991 Oct; 45(4):435-41. PubMed ID: 1659239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal.
    Rijal S; Boelaert M; Regmi S; Karki BM; Jacquet D; Singh R; Chance ML; Chappuis F; Hommel M; Desjeux P; Van der Stuyft P; Le Ray D; Koirala S
    Trop Med Int Health; 2004 Jun; 9(6):724-9. PubMed ID: 15189464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verrucous papillomatous lesion of post-kala-azar dermal leishmaniasis: fine needle aspiration diagnosis of an unusual presentation.
    Bhadani PP; Sen R; Singh RK
    Acta Cytol; 2007; 51(2):252-4. PubMed ID: 17425218
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypersensitivity reaction over lesions of post-kala-azar dermal leishmaniasis mimicking type 1 reaction in leprosy.
    Dhar S; Malakar S
    Int J Lepr Other Mycobact Dis; 1999 Mar; 67(1):66-7. PubMed ID: 10407631
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ECG changes in prolonged treatment of kala-azar with antimony compounds.
    Pandey AK; Kumar M; Thakur CP
    J Assoc Physicians India; 1988 Jun; 36(6):398-9. PubMed ID: 2846508
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.